Similarly, the selective mineralocorticoid receptor antagonist finerenone, by inhibiting ENaC overactivation, achieves a 32% reduction in urinary albumin-to-creatinine ratio (UACR) and a 23% decrease in kidney-related events, marking a therapeutic breakthrough in DKD management (27). The gene discussed is NR3C2; the disease is diabetic kidney disease.